<i>In vitro</i> evaluation of lipidic nanocarriers for mebendazole delivery to improve anticancer activity
Maria‐Luisa TammaPharmacological and Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, JordanHamdi NsairatPharmacological and Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, JordanMohamed El‐TananiCollege of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab EmiratesRazan MadiPharmacological and Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan
2024en
ABI
Аннотация
OBJECTIVE: To enhance the anticancer activity of the repurposed drug mebendazole (MBZ) against A549 cell lines by developing nanostructured lipid carriers (NLCs). SIGNIFICANCE: MBZ, an anthelmintic drug, exhibits anticancer properties primarily through the inhibition of Ran GTPase and mitotic spindle assembly. Enhancing its delivery and efficacy via NLC could provide a novel and effective approach for lung cancer treatment. METHODS: scratch assays. RESULTS: scratch assays revealed that MBZ-NLCs effectively prevented cell-cell contact, further supporting their potential for improved therapeutic efficacy. CONCLUSION: studies and exploration of different administration routes.
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0